168 related articles for article (PubMed ID: 30799343)
1. Inflammatory Hepatocellular Adenoma with Elevated Serum Protein Induced by Vitamin K Absence/Antagonist-II in Adult Males.
Koya Y; Suzuki T; Tai M; Ichii O; Matsuhashi N; Ejiri Y; Miyazawa M; Shibata M; Harada M; Kumabe T; Nakashima O
Intern Med; 2019 Jun; 58(12):1739-1746. PubMed ID: 30799343
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous resection of liver cell adenomas and an intrahepatic portosystemic venous shunt with elevation of serum PIVKA-II level.
Seyama Y; Sano K; Tang W; Kokudo N; Sakamoto Y; Imamura H; Makuuchi M
J Gastroenterol; 2006 Sep; 41(9):909-12. PubMed ID: 17048056
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
[TBL] [Abstract][Full Text] [Related]
4. Liver cell adenoma in a young man with elevated serum PIVKA-II level.
Uto H; Shigehira M; Kawano T; Nagatomo H; Kuribayashi T; Taniguchi S; Koga K; Komada N; Kitamura T; Maruyama T; Tsubouchi H
J Gastroenterol; 1996 Jun; 31(3):441-5. PubMed ID: 8726839
[TBL] [Abstract][Full Text] [Related]
5. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
[TBL] [Abstract][Full Text] [Related]
6. Elevated PIVKA-II is associated with early recurrence and poor prognosis in BCLC 0-A hepatocellular carcinomas.
Wang BL; Tan QW; Gao XH; Wu J; Guo W
Asian Pac J Cancer Prev; 2014; 15(16):6673-8. PubMed ID: 25169507
[TBL] [Abstract][Full Text] [Related]
7. Malignant Transformation of Hepatocellular Adenoma.
Kwok WY; Hagiwara S; Nishida N; Watanabe T; Sakurai T; Ida H; Minami Y; Takita M; Minami T; Iwanishi M; Chishina H; Kono M; Ueshima K; Komeda Y; Arizumi T; Enoki E; Nakai T; Kumabe T; Nakashima O; Kondo F; Kudo M
Oncology; 2017; 92 Suppl 1():16-28. PubMed ID: 27988517
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of PIVKA-II After Living-donor Liver Transplantation for Hepatocellular Carcinoma.
Park MS; Lee KW; Kim H; Choi YR; Hong G; Yi NJ; Suh KS
Transplant Proc; 2017 Jun; 49(5):1109-1113. PubMed ID: 28583537
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma.
Nakagawa T; Seki T; Shiro T; Wakabayashi M; Imamura M; Itoh T; Tamai T; Nishimura A; Yamashiki N; Matsuzaki K; Sakaida N; Inoue K; Okamura A
Int J Oncol; 1999 Feb; 14(2):281-6. PubMed ID: 9917503
[TBL] [Abstract][Full Text] [Related]
10. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Yoon YJ; Han KH; Kim DY
Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
[TBL] [Abstract][Full Text] [Related]
12. Acarboxy prothrombin (PIVKA-II) as a marker of hepatoblastoma in infants.
Motohara K; Endo F; Matsuda I; Iwamasa T
J Pediatr Gastroenterol Nutr; 1987; 6(1):42-5. PubMed ID: 2432210
[TBL] [Abstract][Full Text] [Related]
13. Abnormal plasma prothrombin (PIVKA-II) levels in hepatocellular carcinoma.
Kawaguchi Y
Jpn J Surg; 1989 May; 19(3):296-300. PubMed ID: 2550692
[TBL] [Abstract][Full Text] [Related]
14. Solitary Muscle Metastasis of Hepatocellular Carcinoma to the Biceps Femoris Muscle with Only Elevated Serum PIVKA-II: A Case Report.
Orita K; Sakamoto A; Okamoto T; Matsuda S
Am J Case Rep; 2019 Mar; 20():306-309. PubMed ID: 30846677
[TBL] [Abstract][Full Text] [Related]
15. Fully validated SRM-MS-based method for absolute quantification of PIVKA-II in human serum: Clinical applications for patients with HCC.
Sohn A; Kim H; Yeo I; Kim Y; Son M; Yu SJ; Yoon JH; Kim Y
J Pharm Biomed Anal; 2018 Jul; 156():142-146. PubMed ID: 29702392
[TBL] [Abstract][Full Text] [Related]
16. Unclassified hepatocellular adenoma with histological brown pigment deposition and serum PIVKA-II level elevation: a case report.
Hoshino K; Harimoto N; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Watanabe A; Kubo N; Araki K; Tomomasa R; Nobusawa S; Aishima S; Nakashima O; Shirabe K
Surg Case Rep; 2020 May; 6(1):94. PubMed ID: 32382834
[TBL] [Abstract][Full Text] [Related]
17. Management of Hepatocellular Adenoma: Recent Advances.
Agrawal S; Agarwal S; Arnason T; Saini S; Belghiti J
Clin Gastroenterol Hepatol; 2015 Jul; 13(7):1221-30. PubMed ID: 24909909
[TBL] [Abstract][Full Text] [Related]
18. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry.
Bioulac-Sage P; Rebouissou S; Thomas C; Blanc JF; Saric J; Sa Cunha A; Rullier A; Cubel G; Couchy G; Imbeaud S; Balabaud C; Zucman-Rossi J
Hepatology; 2007 Sep; 46(3):740-8. PubMed ID: 17663417
[TBL] [Abstract][Full Text] [Related]
20. Histological study of PIVKA-II expression in hepatocellular carcinoma and adenomatous hyperplasia.
Miskad UA; Yano Y; Nakaji M; Kishi S; Itoh H; Kim SR; Ku Y; Kuroda Y; Hayashi Y
Pathol Int; 2001 Dec; 51(12):916-22. PubMed ID: 11844063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
